StockNews.com assumed coverage on shares of Oragenics (NYSE:OGEN – Free Report) in a report issued on Thursday. The brokerage issued a sell rating on the stock.
Oragenics Stock Up 1.9 %
Shares of OGEN stock opened at $1.07 on Thursday. The stock has a market cap of $4.79 million, a P/E ratio of -0.12 and a beta of 0.40. Oragenics has a one year low of $1.00 and a one year high of $7.74. The company’s 50-day moving average price is $1.48.
Oragenics (NYSE:OGEN – Get Free Report) last posted its quarterly earnings results on Friday, March 29th. The company reported ($5.48) EPS for the quarter.
Oragenics Company Profile
Oragenics, Inc, a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus.
See Also
- Five stocks we like better than Oragenics
- Why Special Dividends Can be a Delightful Surprise for Income Investors
- MarketBeat Week in Review – 4/29 – 5/3
- 3 Warren Buffett Stocks to Buy Now
- Apple’s Earnings Show Investors Its Strength and Its Weakness
- Most active stocks: Dollar volume vs share volume
- Bargain Alert: 3 Large Caps With Extremely Oversold RSIs
Receive News & Ratings for Oragenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oragenics and related companies with MarketBeat.com's FREE daily email newsletter.
